Risk Factors and Prognosis in Anti-NMDA Receptor Encephalitis Patients with Disturbance of Consciousness

References

• Dalmau J, Graus F, Ropper AH. Antibody-mediated encephalitis. N Engl J Med. 2018;378(9):840–851. doi:10.1056/NEJMra1708712
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63–74. doi:10.1016/s1474-4422(10)70253-2
   PubMed Web of Science ®Google Scholar
• Dalmau J, Armangué T, Planagumà J, et al. An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol. 2019;18(11):1045–1057. doi:10.1016/s1474-4422(19)30244-3
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12(2):157–165. doi:10.1016/s1474-4422(12)70310-1
   PubMed Web of Science ®Google Scholar
• Nosadini M, Eyre M, Molteni E, et al. Use and safety of immunotherapeutic management of N-Methyl-d-Aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol. 2021;78(11):1333–1344. doi:10.1001/jamaneurol.2021.3188
   PubMed Web of Science ®Google Scholar
• Lim JA, Lee ST, Jung KH, et al. Anti-N-methyl-d-aspartate receptor encephalitis in Korea: clinical features, treatment, and outcome. J Clin Neurol. 2014;10(2):157–161. doi:10.3988/jcn.2014.10.2.157
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu G, Jiang M, Chen W, He Y, Su Y. Clinical characteristics and prognosis of severe Anti-N-methyl-D-aspartate receptor encephalitis patients. Neurocrit Care. 2018;29(2):264–272. doi:10.1007/s12028-018-0536-6
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133(Pt 6):1655–1667. doi:10.1093/brain/awq113
   PubMed Web of Science ®Google Scholar
• Aungsumart S, Ha A, Apiwattanakul M. Abnormal level of consciousness predicts outcomes of patients with anti-NMDA encephalitis. J Clin Neurosci. 2019;62:184–187. doi:10.1016/j.jocn.2018.11.033
   PubMed Web of Science ®Google Scholar
• Qiao S, Wu HK, Liu LL, et al. Characteristics and prognosis of autoimmune encephalitis in the east of China: a multi-center study. Front Neurol. 2021;12:642078. doi:10.3389/fneur.2021.642078
   PubMed Web of Science ®Google Scholar
• Mo Y, Wang L, Zhu L, et al. Analysis of risk factors for a poor prognosis in patients with Anti-N-Methyl-D-aspartate receptor encephalitis and construction of a prognostic composite score. J Clin Neurol. 2020;16(3):438–447. doi:10.3988/jcn.2020.16.3.438
   PubMed Web of Science ®Google Scholar
• Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391–404. doi:10.1016/s1474-4422(15)00401-9
   PubMed Web of Science ®Google Scholar
• Mehta R, Chinthapalli K. Glasgow coma scale explained. BMJ. 2019;365:l1296. doi:10.1136/bmj.l1296
   PubMedGoogle Scholar
• Conrad AJ, Chiang EY, Andeen LE, et al. Quantitation of intrathecal measles virus IgG antibody synthesis rate: subacute sclerosing panencephalitis and multiple sclerosis. J Neuroimmunol. 1994;54(1–2):99–108. doi:10.1016/0165-5728(94)90236-4
   PubMed Web of Science ®Google Scholar
• van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19(5):604–607. doi:10.1161/01.str.19.5.604
   PubMed Web of Science ®Google Scholar
• McKeon A. The importance of early and sustained treatment of a common autoimmune encephalitis. Lancet Neurol. 2013;12(2):123–125. doi:10.1016/s1474-4422(12)70319-8
   PubMed Web of Science ®Google Scholar
• Goldsmith PJ. NMDAR PAMs: multiple chemotypes for multiple binding sites. Curr Top Med Chem. 2019;19(24):2239–2253. doi:10.2174/1568026619666191011095341
   PubMed Web of Science ®Google Scholar
• Cruse D, Young GB. The complexity of disorders of consciousness. Clin Neurophysiol. 2016;127(2):1001–1002. doi:10.1016/j.clinph.2015.08.018
   PubMed Web of Science ®Google Scholar
• Webb AC. Consciousness and the cerebral cortex. Br J Anaesth. 1983;55(3):209–219. doi:10.1093/bja/55.3.209
   PubMed Web of Science ®Google Scholar
• Chi X, Wang W, Huang C, et al. Risk factors for mortality in patients with anti-NMDA receptor encephalitis. Acta Neurol Scand. 2017;136(4):298–304. doi:10.1111/ane.12723
   PubMed Web of Science ®Google Scholar
• Lin J, Xiang Q, Liu X, Li J. Risk factors and prognosis in patients with Anti-N-Methyl-D-Aspartate receptor encephalitis requiring prolonged mechanical ventilation. Front Neurol. 2022;13:814673. doi:10.3389/fneur.2022.814673
   PubMed Web of Science ®Google Scholar
• Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci. 2001;184(2):101–122. doi:10.1016/s0022-510x(00)00501-3
   PubMed Web of Science ®Google Scholar
• Vernino S, Geschwind M, Boeve B. Autoimmune encephalopathies. Neurologist. 2007;13(3):140–147. doi:10.1097/01.nrl.0000259483.70041.55
   PubMed Web of Science ®Google Scholar
• Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr. 2010;22(6):739–744. doi:10.1097/MOP.0b013e3283402d2f
   PubMed Web of Science ®Google Scholar
• Mann AP, Grebenciucova E, Lukas RV. Anti-N-methyl-D-aspartate-receptor encephalitis: diagnosis, optimal management, and challenges. Ther Clin Risk Manag. 2014;10:517–525. doi:10.2147/tcrm.S61967
   PubMed Web of Science ®Google Scholar
• Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162(4):850–856.e2. doi:10.1016/j.jpeds.2012.10.011
   PubMed Web of Science ®Google Scholar
• Liba Z, Sebronova V, Komarek V, Sediva A, Sedlacek P. Prevalence and treatment of anti-NMDA receptor encephalitis. Lancet Neurol. 2013;12(5):424–425. doi:10.1016/s1474-4422(13)70070-x
   PubMedGoogle Scholar
• Waters KA, Machaalani R. Role of NMDA receptors in development of respiratory control. Respir Physiol Neurobiol. 2005;149(1–3):123–130. doi:10.1016/j.resp.2005.03.009
   PubMed Web of Science ®Google Scholar
• Liu Q, Wong-Riley MT. Postnatal development of N-methyl-D-aspartate receptor subunits 2A, 2B, 2C, 2D, and 3B immunoreactivity in brain stem respiratory nuclei of the rat. Neuroscience. 2010;171(3):637–654. doi:10.1016/j.neuroscience.2010.09.055
   PubMed Web of Science ®Google Scholar
• Lin KL, Lin JJ. Neurocritical care for Anti-NMDA receptor encephalitis. Biomed J. 2020;43(3):251–258. doi:10.1016/j.bj.2020.04.002
   PubMed Web of Science ®Google Scholar
• Al-Diwani A, Theorell J, Damato V, et al. Cervical lymph nodes and ovarian teratomas as germinal centres in NMDA receptor-antibody encephalitis. Brain. 2022;145(8):2742–2754. doi:10.1093/brain/awac088
   PubMed Web of Science ®Google Scholar
• Wang R, Guan HZ, Ren HT, Wang W, Hong Z, Zhou D. CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis. Seizure. 2015;29:137–142. doi:10.1016/j.seizure.2015.04.005
   PubMed Web of Science ®Google Scholar
• Yu Y, Wu Y, Cao X, et al. The clinical features and prognosis of Anti-NMDAR encephalitis depends on blood brain barrier integrity. Mult Scler Relat Disord. 2021;47:102604. doi:10.1016/j.msard.2020.102604
   PubMed Web of Science ®Google Scholar
• Trewin BP, Freeman I, Ramanathan S, Irani SR. Immunotherapy in autoimmune encephalitis. Curr Opin Neurol. 2022;35(3):399–414. doi:10.1097/wco.0000000000001048
   PubMed Web of Science ®Google Scholar